Short answer
ARDELYX, INC. (ARDX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $121M (up 23.8% year over year) with net income of −$17M.
Q2 2026 key financials · XBRL
- Revenue
- $121M
- +23.8% YoY · +27.9% QoQ
- Net income
- −$17M
- +12.4% YoY · +55.5% QoQ
- Operating margin
- -10.3%
- EPS (diluted)
- −$0.07
- +12.5% YoY · +53.3% QoQ
Source: XBRL data from the ARDELYX, INC. (ARDX) Q2 2026 10-Q on SEC EDGAR. USD.
ARDELYX, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $120.877M, up 24% YoY from $97.662M
- IBSRELA sales $86.243M, up 33% YoY; XPHOZAH sales $31.886M, up 27%
- GTN adjustment rate 34.0% vs 31.3% YoY
- Liquid funds $281.830M vs $264.689M; Term F Loan provided $50.0M
- Operating cash use $38.636M vs $63.799M; cash outlook sufficient for at least one year
Risk Factors
- New regulatory trigger: CMS March 27, 2026 guidance expects ESRD facilities to furnish XPHOZAH under bundled payments
- Most material update: June 26, 2026 appellate ruling affirmed dismissal of Ardelyx’s lawsuit challenging XPHOZAH’s ESRD PPS inclusion
- Revenue risk: XPHOZAH Medicare Part D coverage eliminated January 1, 2025, materially reducing 2025 revenue and expected growth
- Operational risk: Third-party manufacturers may lack capacity to meet IBSRELA and XPHOZAH demand
- Financial risk: Accumulated deficit reached $1.0 billion as of June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARDELYX, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.